By Josh Beckerman
Shares were recently up 18% to $50 after hours.
The company said the T-cell-based based test is the first indication resulting from Adaptive’s TCR-Antigen Map collaboration with Microsoft Corp.
“People who have been unsure about a prior infection will now have another way to know if they had the virus,” the company said. “We have proven that it is possible to read how T cells detect disease in the blood, and this is just the beginning of a pipeline of tests for many other indications,” the company said.
The EUA was based on a clinical validation study showing that T-Detect COVID demonstrated sensitivity of 97.1% from date of diagnosis using RT-PCR, Adaptive said.
Write to Josh Beckerman at josh.beckerman@Fintech Zoom.com
(END) Dow Jones Newswires
March 05, 2021 19:13 ET (00:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Market news on Fintech Zoom.